The biopharma industry, renowned for its rapid innovation and significant contributions to healthcare, currently faces a tumultuous period marked by widespread layoffs. From early 2023 through late 2024, numerous companies have announced substantial workforce reductions, which reflect a time of
Urticaria, commonly known as hives, is a prevalent skin condition affecting up to 20% of the global population at some point in their lives, causing a significant impact on individuals' quality of life. It is characterized by the rapid appearance of raised, itchy welts or wheals on the skin
Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to
In the ever-evolving landscape of biopharmaceuticals, companies face the immense challenge of managing regulated data and documents, which has become more complex due to the surge in global regulations. The increasing necessity for a unified Regulatory Information Management (RIM) solution that
Recent developments and analyst perspectives have spotlighted Arbutus Biopharma (NASDAQ: ABUS), indicating a promising growth trajectory for this biopharmaceutical company. Chardan Capital's recent decision to raise its target price for Arbutus Biopharma from $4.00 to $4.50 signifies a
Biopharmaceutical fermentation systems are at the forefront of modern medicine, playing a crucial role in the production of biological drugs such as therapeutic proteins, enzymes, monoclonal antibodies, and vaccines. These systems are designed to cultivate microorganisms or cells in controlled
In recent developments, Celltrion USA has significantly expanded the availability of its subcutaneous treatment for Crohn's disease and ulcerative colitis, Zymfentra, now accessible to 26 million patients across the United States. This milestone achievement is a result of the company’s s
The recent results of a clinical trial for an oral obesity drug developed by Viking Therapeutics have generated significant interest. The drug has shown promise in early-phase trials, capturing the attention of Wall Street analysts and investors alike. The study results, revealed at a medical
Recent developments in the pharmaceutical industry underscore the volatile nature of advancements and market dynamics affecting prominent companies. The latest updates reveal a mix of struggles and achievements that highlight how pharmaceutical giants are navigating the complexities of drug
The Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) is experiencing a transformative period marked by the recent appointment of Michelle Tarver as its new director. Tarver, a clinical ophthalmologist with extensive experience within the FDA, steps into her l
